Innovation Leads to Disruption
Curative Therapeutics and Novel Healthcare Delivery Models
The end goals are the same: improved patient outcomes and quality of life. Above all, we seek to partner with driven, engaging entrepreneurs, solving the world’s difficult problems.
Recent Life Sciences Investments
Allakos is a clinical-stage biotechnology company developing therapies to treat a variety of allergic and inflammatory diseases. Allakos is primarily focused on eosinophilic gastrointestinal disorders (EGIDs), leveraging industry-leading expertise in eosinophil and mast cell biology. The Company’s lead candidate, antolimab, is currently being tested in clinical trials across several gastrointestinal, skin and ophthalmic diseases.
Ally Therapeutics is a biotechnology company dedicated to solving the immune response issues that limit the safety and efficacy of in vivo gene therapies
Amplitude Therapeutics, Inc. is a private company founded by Cory Sago, Ph.D., and seeded by Arch Venture Partners and Alta Partners. The Board consists of Cory Sago, Julie Sunderland, and Jay Parrish, a founder of VIR Biotechnology with Arch and Alta.
Cory has been working with Amplifying RNA for its use in vaccines that may require the characteristics of Amplifying RNA rather than traditional mRNA for therapeutic dosing. There are potential applications in 4 areas, and Amplitude is conducting experiments to guide the strategy going forward.
Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body’s native protein factories. The Company is precisely engineering B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy.
CuraSen Therapeutics, Inc. is developing drugs targeting a novel mechanism in the brain to restore function, improve symptoms and modify disease in a range of neurodegenerative diseases, including orphan disorders as well as Parkinson’s Disease and Alzheimer’s Disease.
DEM Bio is pioneering the next generation of immunotherapeutics designed to unleash macrophages and other myeloid effector cells to eliminate tumors by targeting novel ‘don’t eat me’ (DEM) and ‘eat me’ (EM) signals on cancer cells and macrophages. Their proprietary CHoMP™ platform (Co-culture with Human Myeloid Phagocytes) will be used to identify unexplored DEM and EM signals in a systematic and unbiased manner via inter-cellular CRISPR screening using tumor cells, primary macrophages, and other innate immune effector cells.
Edgewood Oncology, Inc. was formed to develop BTX-A51, a novel oral multi-kinase inhibitor targeting CK1 and CDK7/9 that activates apoptosis by upregulating p53 and inactivating MCL-1, MYC, and MDM2, in AML, Sarcomas, and Solid Tumors. The compound has been in the clinic and appears to have a unique profile among kinase inhibitors.
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation. eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing both the key virology and immunology hurdles that have impeded its advancement to date and provide commercially-viable products to save and enhance the lives of patients in need
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases. The Company is employing its massively parallel, multiplexed, and unbiased systems to develop therapeutics for autoimmunity, severe allergy, oncology and infectious disease.
Kelonia’s lentiviral vector gene delivery platform uses a simple and elegant solution that builds on decades of research, development, and technical experience to and efficiently deliver genetic cargo only to the desired tissue.
Lassen Therapeutics is a San Diego based developer of antibody therapeutics intended to address serious unmet medical needs. The company is currently operating in stealth mode.
MBrace utilizes a unique antibody discovery methodology called SPARTA. SPARTA combines an in vitro screening step of a naïve human antibody library against tumor targets, with in vivo selections based on tumor-homing capabilities of a pre-enriched antibody pool. This unique approach overcomes several rate-limiting challenges for rapid translation into clinical applications.
Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered Microbial Medicines (GEMMs).
Progentos is developing first-in-class compounds to induce endogenous oligodendrocyte progenitor cells to remyelinate axons in patients suffering from MS and other demyelinating diseases. Combining expertise in chemistry, biology and in vivo models, Progentos discovers and develops novel small-molecule drugs to regenerate tissues in patients with degenerative diseases.
Qihan Biotech is a biopharmaceutical company focusing on genetic editing for xenotransplantation. The Company’s services address the global shortage of organ donors, enabling patients to get required and matched organs when needed and lead a healthy life.
Tyra Biosciences is an Alta-incubated biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.Tyra is combining insights from structure-based drug design (SBDD), kinase biology, computational chemistry and smart clinical development to discover and develop next-gen small molecule therapies that are active against both wild type and mutant targets
Variant Bio is developing therapies that will improve global health by studying the genes of people who are outliers for medically relevant traits.
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of five product candidates targeting hepatitis B virus, influenza A, human immunodeficiency virus, and tuberculosis
Recent Healthcare Technology and Services Investments
BetterVet is a full-service veterinary practice on wheels supported by a powerful digital
platform.
DispatchHealth is redefining health care delivery to offer on-demand care for people of all ages in the comfort of their own home. DispatchHealth’s board-certified medical teams are equipped with all the tools necessary to treat common to complex injuries and illnesses. DispatchHealth works closely with payers, providers, health systems and others to deliver care in the home to reduce unnecessary emergency room visits and hospital readmissions.
Everside Health, formerly Paladina Health, is the second largest direct primary care provider in the U.S., operating 350 health clinics in 32 states located at or near the facilities of its employer, union and other benefit sponsor clients. Everside’s data-driven, patient-centric healthcare delivery model aligns incentives to benefit the patient, the physician and the benefit provider, all while reducing the total cost of care. Patients receive convenient, low- or no-cost access to physicians and 24/7 virtual care, reducing the need for costly ER use.
Free Market Health is a healthcare technology company dedicated to improving the specialty pharmacy ecosystem with a care-driven marketplace platform.
PatientsLikeMe is an online patient community portal, consisting of an online platform offering those with a chronic condition the opportunity to track and share symptoms and treatment experiences, contribute data for research and connect with others who are going through similar situations.
Harbor Health was created by people who have spent decades trying to make health better, including those who provide health to those who figure out how to pay for it. Harbor Health’s mission is to make the entire health system work better for consumers so that everyone can achieve optimal health.
Transcarent is a consumer digital health company that uses a combination of software, technology, and data science to empower consumers with information and access, leading to better outcomes and more cost-effective decisions.
United Musculoskeletal Partners Holdings is a private orthopedics company currently with three large metropolitan markets, multiple outpatient surgical facilities, orthopedics hospitals, and ancillary services, including radiology and physical therapy.